Please login to the form below

Not currently logged in

Shire appoints Soren Tulstrup to lead its MPS franchise

He joins with experience from Santaris Pharma, Merck & Co, Sandoz and Abbott

Soren Tulstrup has joined Shire's Human Genetic Therapies business as franchise lead, MPS (mucopolysaccharides).

He will be responsible for developing global strategy for the MPS franchise, where Shire's current lead product is Elaprase (idursulfase) for Hunter syndrome.

Tulstrup will also play a key role in strategic decisions made about the company's rare disease portfolio, which includes 2010 Prix Galien winner Firazyr (icatibant) and Fabry disease drug Replagal (agalsidase alfa).

In his new role, Tulstrup will report to Sylvie Grégoire, president of Shire HGT, and be based in Shire's office in Nyon, Switzerland.

“Shire HGT is well positioned for continued sustained growth, with a strong portfolio of therapies for patients suffering from rare genetic diseases and a pipeline with significant potential,” said Sylvie Grégoire, president, Shire HGT.

“We believe Soren's extensive global experience will be invaluable in maximising the full potential of the MPS franchise as we provide therapies to patients with rare conditions that enable them to lead better lives,”.

Currently vice chairman of trade association EBE (European Biopharmaceutical Enterprises), Tulstrup was formerly president and CEO of Santaris Pharma, where he led business development efforts resulting in four major partnership agreements, including an ongoing collaboration with Shire.

Prior to this he spent over a decade at Merck & Co, both in Europe and the US, and has also held sales and marketing positions at Sandoz and Abbott Laboratories.

31st July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...